PharmNovo presented at the BioStock Investor Meeting
PharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.
PharmNovo's CEO Per von Mentzer gave a presentation at the BioStock Investor Meeting on September 20 in Stockholm. Watch his presentation about the company's work in developing new treatments for neuropathic pain and how the phase I clinical study, which is in its final phase, is progressing. PharmNovo is now in the final phase of its clinical phase I study and is preparing a phase II study planned to start in 2024.
PharmNovo presented at the BioStock Investor Meeting
PharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.
PharmNovo's CEO Per von Mentzer gave a presentation at the BioStock Investor Meeting on September 20 in Stockholm. Watch his presentation about the company's work in developing new treatments for neuropathic pain and how the phase I clinical study, which is in its final phase, is progressing. PharmNovo is now in the final phase of its clinical phase I study and is preparing a phase II study planned to start in 2024.
Latest news
View all
Reports of broader therapeutic potential for PN6047
PharmNovo AB announces today new preclinical findings supporting the potential of PN6047 in migraine and opioid withdrawal syndrome. The findings were generated through the company's NIDA-funded collaboration with researchers at Washington University School of Medicine.
Read more
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
